8-KLeadership Changes

BIOGEN INC. 8-K Report, Executive Changes (Mar 30, 2009)

Filed March 30, 2009For Securities:BIIB

Summary

Biogen Idec Inc. (BIIB) filed an 8-K on March 30, 2009, to report a significant change in its executive leadership. Robert A. Hamm was appointed as the new Chief Operating Officer (COO), succeeding Hans Peter Hasler. This transition marks a key moment in the company's operational management, with Mr. Hamm bringing extensive experience within Biogen Idec across various senior roles since 1994. The filing details Mr. Hamm's compensation package for his new role, including a base salary of $720,000, an annual cash incentive opportunity targeted at 75% of his base salary, and equity awards consisting of restricted stock units (time-vested and performance-vested) and stock options. The value of these equity awards is approximately $190,000 each and will be based on the company's stock price on April 1, 2009. Investors should monitor how this leadership change impacts operational execution and strategic initiatives.

Key Highlights

  • 1Robert A. Hamm appointed Chief Operating Officer (COO) effective March 30, 2009.
  • 2Hans Peter Hasler resigned from the COO position on March 30, 2009.
  • 3Mr. Hamm has a long tenure with Biogen Inc. and Biogen Idec, holding various leadership roles since 1994.
  • 4Mr. Hamm's new role includes a base salary of $720,000 per year.
  • 5Target annual cash incentive opportunity for Mr. Hamm is 75% of his base salary.
  • 6Mr. Hamm will receive equity awards (restricted stock units and stock options) valued at approximately $190,000 each.
  • 7Equity award values are subject to Biogen Idec's common stock price on April 1, 2009.

Frequently Asked Questions

The 8-K filing states that Hans Peter Hasler resigned from his position as Chief Operating Officer. The specific reasons for his resignation are not disclosed in this filing.

Robert A. Hamm has a long history with the company, holding various senior positions since 1994. His previous roles include Executive Vice President of Pharmaceutical Operations & Technology, Senior Vice President of the Neurology Strategic Business Unit, and leadership roles in sales, marketing, and international operations.

Mr. Hamm's compensation includes a base salary of $720,000 annually, with a target annual cash incentive of 75% of his base salary. He will also receive equity awards, including time-vested and performance-vested restricted stock units, and stock options, each valued at approximately $190,000, to be determined based on the company's stock price on April 1, 2009.

The value of the restricted stock units and stock options granted to Mr. Hamm will be based on the closing price of Biogen Idec's common stock on April 1, 2009, which is the first trading day of the month following his appointment.